This week’s episode of “WisBusiness: the Podcast” is with Ayla Annac, co-founder, president and CEO of Madison-based InvivoSciences.

This pre-clinical stage biotech company is developing a method for creating tissue samples from patients’ blood, urine or skin to test treatments for heart failure. By using artificial intelligence to organize patients into various categories, the company aims to improve precision medicine approaches for treating these patients.

“We can collect the sample directly from the patient group, and we integrated artificial intelligence into our technology platform recently by the help of NIH,” she said. “What this technology does [is] specifically identifies a subgroup of heart failure patients by analyzing the diagnostic parameters for them.”

Click here to read the full article and listen to the podcast.